"UMass-Boston opens business incubator; School aspires to be major research center" by D.C. Denison, Globe Staff | May 1, 2009
"wet" labs for life sciences research, two computer labs, and plenty of glass-enclosed conference rooms and "collaboration spaces."
Isn't that where they develop things like swine flu?
GeoMed Analytical will be developing techniques to detect metals in medical samples. Symmetric Computing will develop advanced supercomputing applications for the life sciences industry. Anthurium Solutions Inc., a software company, is building tools to connect digital workers around the world.
DPixel, based in Milan, represents the funding end of the start-up equation. The venture investment fund will use the center as a base from which to scout for strategic partners for its portfolio companies....
Related: Where Your Pension Went
--more--"
But don't worry; you'll get that money back (right?):
The state's biotechnology industry has grown significantly in recent years, though somewhat slower than hoped, according to a study released yesterday by the Massachusetts Biotechnology Council.
Massachusetts has more than 40,000 biotech jobs, according to the council's 2015 Strategic Plan, up from about 30,000 in 2002. Another council report seven years ago predicted the industry could employ 60,000 by 2010 under the right conditions. But that is unlikely now, given the lagging economy.
We shed half that number of jobs in March alone. Biotech ain't no savior; in fact, it is a drain with the taxpayer $$$ going to pharmaceutical corporations.
And yeah, I'm tired of the promises that never materialize. I call them lies now.
Terry Hisey, vice chairman and US life sciences leader for Deloitte LLP, the New York auditing and consulting powerhouse that helped prepare the latest study, said the global credit crunch has made it difficult for many firms to raise money from venture capitalists and other investors....
That's a lie!!! See: Biotech's Business Agent
Okay, then, which one is the liar?
The rest of the article is nothing more than elitist, self-adulating aggrandizement.
--more--"
I'm sorry; I guess I was wrong again(??):
"Novartis will expand in Cambridge; Drug maker signs lease deal, plans to build a new facility" by Casey Ross, Globe Staff | May 8, 2009
The pharmaceutical giant Novartis AG is planning to build a new facility on Massachusetts Avenue in Cambridge, in the shadow of the Massachusetts Institute of Technology.
Novartis is likely to build a research facility on the site, although no final decisions have been made. "We're committed to Cambridge. This is a long-term investment," said Mark Fishman, president of the company's institute for biomedical research. "We have found it particularly beneficial to have the relationship with MIT, Harvard, and the hospitals in the neighborhood."
So they can have a base to design and test all their poisons?
I mean, look at the globalist cluster-f***!
Novartis already occupies more than a million square feet in Cambridge, much of it in the former Necco candy factory near Central Square. The location is home to its global research unit, and Novartis has recently located its vaccines and diagnostics division in Cambridge, too....
Oh, I used to love Necco's pure sugar wafers when I was a kid! All sorts of flavors and colors.
The Cambridge expansion bucks the trend of biotech firms and other companies moving out of the urban core to the suburbs, where office space is generally cheaper and businesses have more flexibility to expand and to customize facilities. Among those that have left Cambridge is Shire Pharmaceuticals' genetics operations, which decamped to Lexington.
Novartis executives said the Cambridge location gives them access not only to new recruits at MIT and Harvard, but opportunities to collaborate with researchers at universities and teaching hospitals. Real estate specialists said leasing activity in Cambridge is beginning to pick up and that the out-migration of companies has mostly been driven by the need to save money in the soft economy.
"Cambridge continues to be the center of the life-sciences universe for all of the obvious reasons, and that's not going to change," said Mark Winters, of the real estate firm Cushman & Wakefield.
It is true what they say about stuck-up Cambridge elites and their self-centeredness.
Novartis has an array of cancer and diabetes drugs being developed in Cambridge that could be submitted for approval in the next few years....
Yeah, I'll bet they hope those diseases are never cured, 'eh?
And arguing on the ops page for the whole thing:
"Drew Gilpin Faust and Jack M. Wilson Keeping Mass. an innovation leader"
That would be "$436,000 a year" Jack Wilson and the Harvard president, right?
